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Abstract
Objectives. Complement deficiencies are difficult to diagnose
because of the variability of symptoms and the complexity of the
diagnostic process. Here, we applied a novel ‘complementomics’
approach to study the impact of various complement deficiencies
on circulating complement levels. Methods. Using a quantitative
multiplex mass spectrometry assay, we analysed 44 peptides to
profile 34 complement proteins simultaneously in 40 healthy
controls and 83 individuals with a diagnosed deficiency or a
potential pathogenic variant in 14 different complement proteins.
Results. Apart from confirming near or total absence of the
respective protein in plasma of complement-deficient patients, this
mass spectrometry-based profiling method led to the identification
of additional deficiencies. In many cases, partial depletion of the
pathway up- and/or downstream of the absent protein was
measured. This was especially found in patients deficient for
complement inhibitors, such as angioedema patients with a C1-
inhibitor deficiency. The added value of complementomics was
shown in three patients with poorly defined complement
deficiencies. Conclusion. Our study shows the potential clinical
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utility of profiling circulating complement proteins as a
comprehensive read-out of various complement deficiencies.
Particularly, our approach provides insight into the intricate
interplay between complement proteins due to functional coupling,
which contributes to the better understanding of the various
disease phenotypes and improvement of care for patients with
complement-mediated diseases.
Keywords: complement deficiencies, complement system,
complement-mediated diseases, complementomics, multiplex
targeted mass spectrometry, pathway analysis
INTRODUCTION
The complement system is a proteolytic cascade
that orchestrates innate immune surveillance,
homeostasis and repair. It comprises about 50
circulating fluid-phase and surface-bound
proteins. They are constitutively expressed by
many cell types in different tissues, whereas the
blood circulating complement proteins are mainly
of hepatic origin.1
Despite the fact that the complement system is
highly conserved,2 the genes encoding the
complement factors contain many polymorphisms,
with remarkable geographical variation3 and
unique complotypes.4 Most variants are benign or
of undetermined significance, and several are
reported to be protective,5–8 while rare variants
are often pathogenic and result in complement
deficiency.9 The clinical manifestations range from
severe infections, neuro-degenerative diseases,
haematological disorders, to renal or ocular
pathologies, as reviewed extensively elsewhere9–13;
a tabular overview is provided in Supplementary
table 1.
Complement deficiencies are rare and have a
combined genetic prevalence of 0.03% in the
general population and comprise only 5% of all
primary immunodeficiencies – excluding more
frequently occurring C4A, C4B and MBL variants
(estimated 11–22%, 30–45% and 5–10%,
respectively).14 The mode of inheritance is mostly
autosomal recessive, with the exception of a few
cases of autosomal dominant inheritance: CR1,
C1S, C1-inhibitor (C1-INH), mannose-binding lectin
(MBL), and properdin (X-linked).12 For factor H,
both recessive and dominant modes of
inheritance have been reported depending on the
type of disease.15 Moreover, for several
complement-mediated diseases – including
acquired angioedema (AAE), systemic lupus
erythematosus (SLE), age-related macular
degeneration (AMD), atypical haemolytic uremic
syndrome (aHUS) and membranoproliferative
glomerulonephritis (MPGN) – genetic and non-
genetic multifactorial components play a role in
disease aetiology. In addition, given the central
role of the complement system in immunological
mechanisms, complement deficiencies may be (in-)
directly involved in multiple other diseases.
The diversity in clinical symptoms necessitates
laboratory testing to diagnose the complement
deficiency. Conventionally, the classical, lectin, or
alternative pathway activity is tested using
functional assays (CH50, LP50 and AH50,
respectively), followed by single tests measuring
individual proteins of the affected pathway to
identify the impaired protein.14,16 Unfortunately,
this testing strategy has some major shortcomings.
Functional assays may not always rule out certain
deficiencies,12 and for most complement proteins,
no standardised tests are available. The current
protein analysis is primarily based on ELISA, radial
immunodiffusion, immunoelectrophoresis or
nephelometry,13 which are either time consuming,
have limited accuracy or require relatively large
sample volumes, respectively. Furthermore, the
complement system is sensitive to freeze–thaw
cycles, which could lead to complement activation,
interfering with the measurements. Complement
deficiencies are increasingly investigated by genetic
testing which provides molecular comprehension
of inherited predispositions. However, this provides
limited information on the functional
consequences and there is thus a clear need for
diagnostic profiling of all complement proteins
simultaneously as this will provide an immediate
overview of deficiencies at protein level. Two
independent studies including large cohorts of
complement-deficient patients used a single
method to confirm the genetic variant (functional
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testing, ELISA, radial immunodiffusion or
nephelometry); however, no extensive protein
profiles were determined.17,18 Hence, sensitive and
quantitative methods analysing all complement
proteins of the complement system in multiplex
have not been applied to characterise complement
deficiencies yet.
To the best of our knowledge, this is the first
study to profile 34 circulating complement factors
in plasma from patients with distinct complement
deficiencies using quantitative multiplex mass
spectrometry. Unravelling the downstream effects
of deficiencies on other proteins of the
complement system will lead to a better
understanding of the disease phenotypes,




For this study, plasma samples from 83 patients and
40 control subjects were collected from four
European medical centres in the Netherlands, Italy
and Spain. We included material of 10
homozygous, 2 compound heterozygous, 4
hemizygous and 24 heterozygous variants. For 9
patients, we did not have genetic confirmation for
the zygosity of the mutation, and the diagnosis
was established only on protein level. Five patients
diagnosed with AAE were also included.
Furthermore, we included 26 subjects with
(predicted) pathogenic heterozygous nonsense
variants – complement C3 (n = 1), C6 (n = 1), C9
(n = 8), factor D (n = 5), factor H (n = 8) and factor
I (n = 3). We also included three unknown clinical
cases suspected of having a complement deficiency
based on clinical symptoms. Additional clinical and
molecular data from patients and healthy subjects
enrolled in this study are summarised in
Supplementary table 2. In total, this cohort was
comprised of variants in 14 different complement
proteins (Figure 1a), in multiple age groups
(Figure 1b) and both sexes (Figure 1c).
Effect of variants on the deficient protein
expression levels
We analysed 44 peptides in a multiplex targeted
mass spectrometry method, enabling quantitative
detection of 34 complement proteins
simultaneously. A table with the absolute
concentrations is included in Supplementary table 3.
Individuals with the same genetic variant were
grouped (rows), and the percentages were
calculated for the concentration of each peptide
(columns) as compared to the control group average
(Figure 2). The homozygous (C1Q n = 2, C6 n = 2,
and C8 n = 3), hemizygous (properdin n = 4) and
heterozygous dominant inherited variants (C1-
inhibitor n = 23, MBL n = 4) could be distinguished
by very low or absent levels of the corresponding
peptide(s). For a few homozygous variants, reduced
levels were measured: factor B (Leu9His, n = 2;
Gly252Ser, n = 1) and factor I (Asp519Ans, n = 1),
60% and 30% respectively, whereas for factor H
(Val1007Leu, n = 1) normal levels were observed.
For most heterozygous nonsense variants, we
measured lower levels for the corresponding
peptides: C9, factor D, factor H and factor I
(Supplementary table 3). An overview of the t-test P-
values (after Bonferroni correction) for all peptides
for each patient group compared to the control
group is shown in Supplementary table 4.
Collateral effect of variants
on the complement levels of
the affected pathway(s)
Apart from the anticipated lower levels for the
defined homozygous, hemizygous and pathogenic
heterozygous variants, in many cases additional
lower levels of other complement proteins down-
or upstream were observed in the cascade. For
instance, for patients with (acquired) C1-inhibitor
deficiency in acquired and hereditary angioedema
type I (AAE and HAE1), we observed that other
classical pathway proteins including C1QA (AAE
6%, HAE1 37%), C1QC (AAE 4%, HAE1 33%), C1R
(AAE 6%, HAE1 54%) and C1S (AAE 7%, HAE1
61%) were significantly reduced, indicating
consumption of the classical pathway due to
impaired inhibition. Collectin-11, one of the
activators of the lectin pathway, was significantly
reduced as well (AAE 44%, HAE1 59%), which
might imply consumption of the lectin pathway
due to improper inhibition. Also, several peptides
downstream, C2 (AAE 3%, HAE1 39%), C3 (AAE
15%, HAE1 26%), C4 (AAE 2%, HAE1 8%), in the
alternative pathway (FB both 50%, PROP HAE1
60%), terminal pathway (C5 50%, C8 50%, on
average) and their regulation factors (CFH, CFI,
C4BP, vitronectin, FHR2, FHR4 and FHR5, 20–70%)
show significant reduction, Figure 3 (AAE) and
Supplementary figure 1a (HAE1).
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For deficiencies in the classical pathway (C1Q),
there was no significant reduction of other
complement components. The MBL variants (lectin
pathway) showed additional reduced C1-INH,
C1QC and vitronectin levels. For variants in
alternative pathway components FD and PROP,
we only observed a significant decrease of C1-INH,
C3 and C5 or C8, whereas the factor B variants
had no up- or downstream effects. Variants of
complement proteins in the terminal pathway (C6,
C8, C9) coincided with altered levels of upstream
components like C3, properdin, C5 and C6 and
possible downstream effects on membrane attack
complex (MAC) regulators clusterin and
vitronectin. Regulating factor H and factor I
variants also showed reduced alternative and
terminal pathway components, but only the
reduced clusterin levels were significant. A
pathway visualisation of all variant groups is
represented in Supplementary figure 1a–k.
Clinical cases with a suspected complement
deficiency
Three patient samples with a suspected
complement deficiency without immunological or
genetic data were included in order to validate
this multiplex mass spectrometry-based assay as a
method to screen for complement deficiencies.
• Patient #45 had recurrent late pregnancy loss in
the 2nd trimester without known causes. Since 4
other patients with a comparable medical
history (#42–44 and #72 in this study) showed
low to undetectable MBL levels, an MBL
deficiency was suspected for patient #45 as well.
However, the multiplex assay showed elevated
levels for MBL, but undetectable MASP1 and
low levels for factor B, factor D and factor I
(Figure 2).
• Patient #71 is a sister of patient #35 (C6
deficiency), and she was therefore tested for a
potential C6 deficiency. However, patient #71
had normal C6 levels, but very low MBL levels,
which was later also confirmed by additional
analysis.
• Patient #73 is a brother of patient #39, who was
diagnosed with SLE (homozygous C1Q
mutation). Low levels of both C1Q subunits
were measured, whereas C1R, C1S, C2, C4
(downstream) and C1-INH (upstream) had
normal to slightly increased levels. Additionally,
reduced MBL levels were detected and factor D
was below the detection limit. Higher levels of
CFB and properdin, downstream of CFD,
may indicate accumulation due to impaired
factor D. Increased levels for MASP1 and FCN3































Figure 1. Schematic overview of the distribution of (a) zygosity of mutations in complement genes, (b) age and (c) sex of the patients (n = 83).
In acquired angioedema (AAE), auto-antibodies against C1-inhibitor result in lower C1-INH levels instead of a genetic cause. See Supplementary
table 2 for additional clinical and molecular data.
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DISCUSSION
In this study, we screened 34 different
complement proteins simultaneously by analysing
44 peptides in a multiplex targeted mass
spectrometry method in plasma of 83 patients and
40 controls. This resulted in a comprehensive
profile of the blood circulating complement
proteins and provided a proof-of-principle
that our assay has the potential to be
















































Figure 3. Schematic pathway visualisation of the average profile of five acquired angioedema (AAE) patients with an acquired C1-inhibitor
deficiency (green border). The gradient colours of the proteins specify the percentage of the peptides (blue = 0–75%, grey = 75–125%, and
red = 125–200%) as compared to the average value of the control group (n = 40). Thick borders indicate significant reduction (t-test, P-values in
Supplementary table 4). The arrows illustrate the main function of the protein within the cascade: forming a complex (grey pointed arrow),
activation (black dashed pointed arrow) or inhibition (red blocking arrow).
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The development, accuracy and reproducibility of
the assay have been established previously.19 The
assay was further improved by implementing pure
(> 98%) instead of crude (> 50%) heavy isotope-
labelled internal peptide standards for absolute
quantification. For clinical implementation, the
assay needs additional diagnostic validation,
according to clinical mass spectrometry standards.20
Although many complement proteins have a
broad dynamic range due to individual
complotypes, we were able to differentiate














































Figure 4. Pathway visualisation of the relative protein levels of the case of patient #73 with a suspected complement deficiency. The colours
indicate the percentage of the peptides as compared to the average value of the control group (n = 40). The gradient colours of the proteins
specify the percentage of the peptides (blue = 0–75%, grey = 75–125%, and red = 125–200%) as compared to the average value of the control
group (n = 40). The arrows illustrate the main function of the protein within the cascade: forming a complex (grey pointed arrow), activation
(black dashed pointed arrow) or inhibition (red blocking arrow). Candidates for suspected deficiency and further confirmation are highlighted by
green circles: C1Q (subunits C1QA and C1QC), MBL2 and factor D.
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complement deficiencies, showing comparable
profiles for similar deficiencies. In general,
homozygous, hemizygous or heterozygous
(autosomal dominant) deficiencies exhibited very
low levels or total absence of the respective
protein in plasma. Significantly lower levels of the
affected protein were detected in case of
pathogenic heterozygous (nonsense) variants. In
many cases, we observed an additional reduction
through functional coupling of complement
factors within the pathways down- or upstream of
the deficient protein, although not fully depleted.
That other complement proteins were not totally
depleted, especially when a complement inhibitor
is deficient, emphasises the previously observed
resilience of the complement system19 – even in
severe complement deficiencies.
For cases of a complement inhibitor deficiency
such as (acquired) C1-INH deficiency in AAE and
HAE1, systemic complement activation was a
prominent finding. The classical pathway and part
of the lectin pathway seemed to be partially
consumed, due to impaired C1- and MASP-
complex inhibition by C1-INH, as shown by the
lower levels of proteins in both pathways (C1Q,
COL11, C2, C4) for AAE (Figure 3) and to a lesser
extent for HAE1 (Supplementary figure 1a). These
findings are consistent with the clinical
characteristics of AAE and HAE1.21–24 Moreover,
the reduced complement levels in the alternative
and terminal pathway, including inhibitors,
indicate further increased activation. C1-INH
deficiency thus results in hyperactivation through
the classical and lectin pathway, and conceivably
additional complement C3 and C5 cleavage or
factor H and C4BP binding via the extrinsic
(coagulation) pathways,25 causing partial
consumption of other parts of the complement
system.
A patient diagnosed with SLE, caused by a
homozygous C1Q mutation, showed very low
levels of the measured C1QA and C1QC subunits.
No other complement protein levels were affected
by this deficiency, which was expected since the
absence of C1Q protein would block complex C1
formation and subsequent complement activation
via the classical pathway.
All four individuals with a C6 mutation showed
undetectable levels of complement C6, despite the
difference in zygosity of the mutations
(homozygous, heterozygous and compound
heterozygous). We found significantly reduced
protein levels both upstream in the classical
pathway and downstream in several regulating
factors. Very low or no complement C6 would
result in reduced or blocked MAC building.
However, we observed a reduction in MAC
inhibitor proteins clusterin and vitronectin in
these patients, with a similar trend for other
terminal pathway variants (in C7, C8, C9), whereas
we would expect an increase of MAC inhibitors.
This leads to the hypothesis that there is either a
reduced trigger to synthesise the MAC inhibitors
or they are partly depleted as a result of constant
clearance of tissue damage caused by perpetual
complement activation and inflammation.26,27
Factor H-related (FHR) proteins did not show
large variation between the groups, except for
significantly reduced levels of FHR-1 and FHR-2 in
C6 deficiencies and FHR2, FHR4 and FHR5 in the
HAE1 group. The functions of FHR proteins
remain largely unknown. However, recent data
suggest that they primarily promote complement
activation: FHR-1, FHR-4 and FHR-5 can bind C3b
allowing convertase formation and in this way
prevent inhibition by factor H.28 Contrary,
another study concludes that FHR-1 can inhibit C5
convertase and MAC formation.29 Increased levels
of FHR-5 have been associated with inflammation
or infection before.30 This assay enables the study
of FHR proteins in relation to other complement
proteins, which may contribute to the better
understanding of their function in the future.
In this patient cohort, we observed a remarkable
high frequency (38.0%) of low MBL concentrations
(< 11 mol L1, as was also observed for the
diagnosed primary MBL deficiencies) in addition to
the diagnosed complement deficiency, which was
significantly higher as compared to 12.5% for the
control group (P = 0.004, Chi-square test). MBL
variants have a frequency of 5–10%, which is
consistent with our findings, and are suspected to
have only a redundant role in severe infections.31,32
However, multiple studies suggest that an MBL
deficiency, causing lower levels, might predispose
to the development of more severe symptoms in
combination with other (complement)
deficiencies.33–35 The fact that we find this high
occurrence seems to support this view.
Four patients with a diagnosed MBL deficiency
experienced recurrent late pregnancy losses,
which may be related to low MBL levels.36,37
However, after testing in this multiplex assay,
these patients also showed additional decreased
classical components C1QC and C1-INH, while this
was not observed in the MBL-deficient controls.
2020 | Vol. 9 | e1225
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Other reports describe associations between
reduced C1Q levels and abnormal placentation
and foetal loss.38 It may thus be interesting to
speculate that low C1Q and C1-INH levels, in
combination with low MBL, may contribute to
recurrent late pregnancy loss. A profile of all
plasma complement components thus provided
new leads for understanding complications of
these patients, but still needs confirmation by
clinically validated single protein tests.
We investigated the application of this multiplex
assay for three patients with a suspected
complement deficiency. Analysis of the blood
concentrations of 34 complement proteins
provided a quick overview of affected proteins. We
identified reduced levels of MASP1, factor B, D and
I in patient #45, suggesting a defect in the
alternative pathway: factor I deficiency could cause
partial depletion of MASP1, factor D and B, as a
similar trend was observed in the included
diagnosed factor I deficiencies. The C6 levels of
patient #71 were normal, so she does not have a C6
deficiency like her brother (#35). However, finding
very low MBL levels in both siblings emphasises the
possibility of a combined C6/MBL deficiency for
patient #35, which was discovered using this assay.
Patient #73 had reduced levels for factor D, MBL
and C1Q. Since his brother (#39) has been
diagnosed with a homozygous C1Q deficiency, it is
likely that this patient also has a C1Q deficiency,
although an additional MBL and/or factor D
deficiency could not be ruled out. In conclusion,
our assay rapidly identified plausible deficient
proteins for further testing. These findings
demonstrate the added value of this multiplex
assay, as it substantially reduces the number of
clinical tests needed for systemic diagnosis, leaving
only the aforementioned candidate proteins for
each patient that need follow-up confirmation by a
diagnostic – functional or genetic – test.
The effect of missense mutations was more
difficult to interpret, as many of those mutations
may not have translational consequences (silent
mutations). For instance, the homozygous factor
H variant (Val1007Leu), which is a reported
polymorphism with no functional significance,39
shows normal blood levels and thus confirms that
this variant has no effect on protein expression
levels. However, these findings do not exclude a
functional deficiency, as the targeted peptide
might not be affected. Also, the homozygous
factor B Leu9His (rs4151667) (n = 2) variant is
likely benign for C2D and aHUS40 and protective
for AMD.41 Yet, in this multiplex assay we found
that this variant resulted in ~ 60% of the control
levels (although statistically not significant),
confirming earlier larger studies.42
This method is developed to measure
complement levels and does not allow the
measurement of complement activation products,
because the enzymes used for protein digestion
cleave at the same sites as the proteases of the
complement system. To study these activation
products by mass spectrometry, the sample
preparation and method have to be designed
differently, for instance by applying other
enzymes or the use of tags that target
neoepitopes created upon activation.
The increasing implementation of next-
generation sequencing in clinical diagnostics will
lead to an upsurge in demand for phenotypic
analyses especially considering the high
polymorphism rates for complement genes and
the multifactorial and non-genetic causes of
complement-mediated disease. The high
specificity and the requirement of just a few
microlitres make it attractive to implement this
multiplex approach in routine diagnostics to
profile the complement system. Longitudinal
studies could provide more insight in disease
progression of autoimmune diseases and
coagulation disorders or could be used to monitor
the (off-target) effects during treatments such as
complement replacement therapy (C1-inhibitor),
complement-targeting drugs or biologicals
(eculizumab), vaccination or immunosuppression.
Thus, by personalised monitoring of the
‘complementome’ we will be able to broadly
study (new) genetic variants of complement genes
to better understand the disease phenotypes and
improve the care for patients with complement-
mediated diseases.
METHODS
Study approval for patients and healthy
donors
For this study, a group of 83 patients, either diagnosed with
a complement deficiency or a predicted pathogenic
complement variant, were collected from four European
medical centres in the Netherlands, Germany, Spain and Italy.
Each complement deficiency had been confirmed previously
by genetic analysis, ELISA or radial immunodiffusion. Patients
with AMD were screened by means of exome chip
genotyping,43 exome sequencing44 and single-molecule
molecular inversion probes combined with next-generation
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sequencing.45 Additionally, we included three cases with a
suspected but undiagnosed deficiency.
Patients above 12 years of age or parents/guardians of
children below the age of 12 provided written informed
consent for blood sample collection for complement
diagnostics, and residual plasma samples specifically
collected for complement diagnostics were used for this
study as approved by the medical ethical committees of the
Radboud University Medical Center in Nijmegen; the
University Hospital Cologne, Germany; the University of
Milan, Italy; and Hospital Clınico Universitario de Santiago
de Compostela, Spain.
Plasma samples from 10 healthy donors (aged 25–54) and
30 healthy controls (aged 65–81, without variants associated
with AMD, determined by exome chip genotyping and
exome sequencing) were collected after informed consent
according to the guidelines of the central committee on
research involving human subjects Arnhem-Nijmegen.
Selection criteria included equal sex distribution, no fever
(> 38.5°C) and CRP values of < 130 mol L1 ( 3 mg L1) to
exclude infection, inflammation and chronic illness.
Sample collection and preparation
Only samples with a low number of freeze–thaw cycles
(max. two times and processed on ice) were included.
Plasma samples were shipped on dry ice and stored at
80°C upon arrival. They were thawed on ice and prepared
in a randomised order. The preparation and analysis were
performed according to an optimised version of the
previous method.19 A subset of 44 peptides was selected
based on performance and redundancy for the current
assay (Supplementary table 5). The sample preparation was
automated using a pipetting robot (TECAN, M€annedorf,
Switzerland). Without any sample pre-treatment, the
plasma samples were pipetted in a 96-well plate and
denatured in 4.0 M urea. The proteins were reduced with
3.3 mM dithiothreitol for 30 min at RT. Reduced cysteines
were alkylated through incubation with 12.5 mM 2-
chloroacetamide in the dark for 20 min at RT. Next, the
samples were diluted (1.259) and digested with a protease
mix of LysC and Trypsin in 50 mM ammonium bicarbonate
(1 µg LysC and 1 µg Trypsin per 50 µg protein) by shaking
incubation at 37°C for 4 h. The digests were spiked with a
mix of > 98% pure C-terminally 13C15N stable isotope (Arg-
10 or Lys-8)-labelled peptides (Pepscan, Lelystad, The
Netherlands) and stored at 80°C until analysis.
Mass spectrometric analysis
Prior to analysis, the samples were desalted using Bond Elut
OMIX tips (Agilent, Santa Clara, CA, USA). The eluates were
evaporated to a few microlitres to remove organic solvent
using a vacuum concentrator (Thermo Fisher Scientific,
Waltham, MA, USA) at 45°C for 25 min. Samples were
reconstituted in 0.1% formic acid. All peptides containing a
methionine were oxidised with 0.3% peroxide prior to
analysis to obtain 100% methionine oxidation and were
measured separately. Each sample was then injected over a
trap column (Waters Acquity UPLC MClass symmetry C18,
100 A, 5 µm, 300 µm 9 50 mm), using the Waters Acquity
MClass UPLC, onto an iKeyTM (Waters peptide BEH C18, 130 A,
1.7 µm, 150 µm 9 100 mm) situated in the Waters Xevo TQ-S
ESI source (Waters, Milford, MA, USA). The peptides were
eluted from the iKey using a linear gradient from 3% to 35%
acetonitrile in 0.1% formic acid in 20 min at a flow rate of
2 µL min1. The peptides were analysed in positive ESI mode
using 1-min multiple reaction monitoring (MRM) windows.
Mass spectrometer parameters were optimised for each
respective peptide prior to analysis of the sample cohort. A
detailed overview of all measured peptides and selected
transitions is provided in Supplementary table 5.
Data processing and statistical analysis
The light/heavy ratios for each endogenous and
corresponding heavy isotope-labelled peptide were
determined using Skyline software v19.1.0.193 (MacCoss
Lab, University of Washington, USA). Typical settings
applied included default peak integration, no peak
smoothing, SSRCalc window of 10 arbitrary units, Q1 mass
window of 0.7 Th, Q3 window of 1.0 Th, considered
isotopes up to 3 amu. The data set was manually inspected
to ensure correct peak detection and integration. Peaks
that failed manual evaluation had poor technical quality
indicators such as < 0.75 dot product (ratio of the
transitions as compared to the human plasma spectral
library (Human_plasma_2012-08_all.splib.zip, build by H.
Lam (2012), available at the PeptideAtlas website: http://
www.peptideatlas.org/speclib/) or < 39 signal-to-noise ratio.
They were excluded and reported as ‘invalid’ or ‘below
limit of detection’ (< LOD), respectively. We used > 98%
pure heavy isotope-labelled peptides (Pepscan, Lelystad,
The Netherlands) to determine the concentration of the
corresponding endogenous peptides.
IBM SPSS Statistics v25.0.0.1 and R v3.6.3 (RStudio
v1.2.1335) build in packages were used for data exploration
and statistical analysis. To increase statistical power,
patients with an identical diagnosed genetic variant were
grouped. First, the homogeneity of variance was assessed
for the patient groups and control group by Levene’s test,
followed by an independent samples Student’s t-test (equal
variance assumed) or the Welch t-test (unequal variance
assumed) to compare the patients to the controls.46 A post
hoc multiple testing correction was performed by
multiplying the P-values with a Bonferroni-correction factor
(for unequal sample sizes): 704 (44 peptides, 16 groups).
Proportions (cells with expected count ≥ 5) were compared
by means of the Chi-square test. CytoScape v3.8.0 was used
for pathway visualisation.
Data sharing
The Skyline files and raw data files can be found online in
the Panorama public repository: https://panoramaweb.org/
CS_MRM_Cdef.url (ProteomeXchange: PXD022416).
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